Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
about
RNA and diseaseInhibition of RNA Interference and Modulation of Transposable Element Expression by Cell Death in DrosophilaAnalysis of siRNA specificity on targets with double-nucleotide mismatchesSynthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA.Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.Possibilities for RNA interference in developing hepatitis C virus therapeutics.Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumorsMulti-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma.Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.Silencing of tumor necrosis factor receptor 1 by siRNA in EC109 cells affects cell proliferation and apoptosis.Use of liposomes as drug delivery vehicles for treatment of melanoma.siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer.Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach.Potential clinical applications of siRNA technique: benefits and limitations.MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs.Engineering Nanocarriers for siRNA Delivery.Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models.Synthesis and characterization of Fe3O4-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system.Review of Methods to Study Gene Expression Regulation Applied to Asthma.In vivo delivery of functional Flightless I siRNA using layer-by-layer polymer surface modification.The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice.Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A.Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2.Reflections on the inhibition of RNAi by cell death signalingTargeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma.Adjustable under-expression of yeast mating pathway proteins in Saccharomyces cerevisiae using a programmed ribosomal frameshift.(18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptorGlutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras.Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases.Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing.Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma.
P2860
Q29615183-450B1893-3B73-46D1-BEA3-D04B3A4316BAQ30053985-58236CA8-3090-4FE8-B0C5-0FBE44DC5DF9Q33329034-FB79B03B-5DC7-442B-BC44-590FC69E5AC9Q34001975-FAA47D00-E76C-4E69-B0ED-3E6CF07D5400Q34293616-0AB7BF16-012C-421A-B64D-8C6E856876EFQ35261143-0B56A92A-8B6D-4E0E-8482-57800FE1B0E8Q35927368-F9143D59-8F27-4953-9153-B9B9E35F57CBQ36659255-412F5973-A99A-4126-9E77-2F46C90D4D6CQ36795709-F0963281-3CDC-471D-BC98-386FF0A5430DQ37068023-947C10C3-5FBE-49E6-A4CF-B68B3137953FQ37073265-19FC0F9E-3812-42EB-8B85-ADBBCA3F6A2AQ37383643-51C95657-A1B7-486C-92E2-958B08CCA325Q37406217-5B16FD8A-59D1-47B9-B145-A6BD17B9FAC6Q37718205-CA6E91EA-C727-41F4-A411-D4309D899F7DQ37756991-BD494992-B48F-430B-A129-A43E123194D9Q37801965-7ABD7A97-D4E3-4D8B-B8D9-1A03F5A53FD3Q37828424-D55B9253-34A9-4C35-ACC7-149444EDB250Q37849727-2E4D7504-EC46-435B-A8CA-9B0B8D96EBD6Q38028653-5D7E899C-7EB4-4AA9-AB42-AE7D58D2A3E4Q38772046-D718EE3D-8CF1-4391-B495-434540B4E8CCQ38864963-1BB89922-23DE-44E6-A04C-F0254A59DEEAQ38891389-EAF4471E-2B28-49DB-9D3D-5C4E8F1BB3C8Q39508981-FD996748-157F-406B-9D45-1F1F554AC551Q39891644-04DAAD66-7C31-48F0-BB25-19725CCA5BF9Q39999697-539C2811-7030-46DB-87EC-FB383A8CF95EQ40655914-6B1B7E3F-1C4B-4495-81BD-0E32489DF6D8Q40783176-0142545C-89B9-4958-ACE7-E5CD7A313B31Q40935292-ACB52794-B5EC-4FBC-9B3D-D60EB1A16659Q41871389-B40BDFCA-37D2-45AF-97CD-3FC6F2BEC9EAQ44791097-D7DDCBC1-E192-47EF-ABBD-04F05ACC9C62Q47127282-F8110DA8-9E69-4267-9D91-461990B3E504Q48030459-DCD22988-57A1-40A6-8D71-BF09C391C549Q53229270-3A8AE39E-6C9D-4550-8D47-5E37CC7845A0
P2860
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@ast
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@en
type
label
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@ast
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@en
prefLabel
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@ast
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@en
P2860
P1476
Applications of RNA interferen ...... iRNA-based strategies in vivo.
@en
P2860
P2888
P356
10.1007/S00253-007-0984-Y
P407
P50
P577
2007-04-25T00:00:00Z